We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
-14.57%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$2.18B
AUM Growth
-$215M
(-9%)
Cap. Flow
+$233M
Cap. Flow
% of AUM
10.67%
Top 10 Holdings %
Top 10 Hldgs %
53.45%
Holding
100
New
9
Increased
46
Reduced
19
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$61.3M |
| 2 |
Biogen
BIIB
|
+$45.5M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$37.2M |
| 4 |
Merck
MRK
|
+$26.9M |
| 5 |
STJ
St Jude Medical
STJ
|
+$25.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$26.6M |
| 2 |
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
|
+$25.4M |
| 3 |
OMED
OncoMed Pharmaceuticals, Inc.
OMED
|
+$25.3M |
| 4 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$21.7M |
| 5 |
Halozyme
HALO
|
+$16.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Biogen
BIIB
$30.4B
| $182M | 8.36% |
625,096
+137,664
| +28% | +$45.5M |
|
|
2
Gilead Sciences
GILD
$167B
| $182M | 8.35% |
1,856,458
+552,051
| +42% | +$61.3M |
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $137M | 6.28% |
1,267,158
+9,600
| +0.8% | +$1.19M |
|
|
4
Regeneron Pharmaceuticals
REGN
$70.9B
| $114M | 5.2% |
244,100
+69,200
| +40% | +$37.2M |
|
|
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
| $113M | 5.17% |
721,593
+64,068
| +10% | +$11.7M |
|
6
BioMarin Pharmaceuticals
BMRN
$11.5B
| $102M | 4.68% |
969,823
+3,946
| +0.4% | +$527K |
|
7
Incyte
INCY
$23.4B
| $97.9M | 4.48% |
887,051
-23,063
| -3% | -$2.59M |
|
|
FOLD
8
DELISTED
Amicus Therapeutics
FOLD
| $85.5M | 3.92% |
6,111,227
+1,106,905
| +22% | +$17.4M |
|
9
Amgen
AMGN
$198B
| $76.7M | 3.51% |
554,697
-11,800
| -2% | -$1.86M |
|
10
Vertex Pharmaceuticals
VRTX
$123B
| $76.5M | 3.5% |
734,200
+135,400
| +23% | +$17.4M |
|
11
Thermo Fisher Scientific
TMO
$198B
| $74.1M | 3.39% |
605,636
+15,600
| +3% | +$2.03M |
|
|
12
Merck
MRK
$315B
| $54.2M | 2.48% |
1,150,050
+506,744
| +79% | +$26.9M |
|
13
Pfizer
PFE
$143B
| $53.7M | 2.46% |
1,803,411
-123,868
| -6% | -$3.97M |
|
|
SGEN
14
DELISTED
Seagen Inc. Common Stock
SGEN
| $48.9M | 2.24% |
1,269,075
+7,000
| +0.6% | +$315K |
|
|
PTLA
15
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $46.4M | 2.12% |
1,088,118
-81,012
| -7% | -$3.91M |
|
|
AGN
16
DELISTED
Allergan plc
AGN
| $38.6M | 1.77% |
142,009
-19,022
| -12% | -$5.84M |
|
|
ICPT
17
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $36.4M | 1.67% |
219,647
+42,000
| +24% | +$9.24M |
|
|
18
Halozyme
HALO
$9.23B
| $35.9M | 1.64% |
2,671,051
-806,000
| -23% | -$16.2M |
|
19
Medtronic
MDT
$106B
| $35.2M | 1.61% |
525,952
+6,123
| +1% | +$451K |
|
20
Teva Pharmaceuticals
TEVA
$37.3B
| $33.6M | 1.54% |
594,950
+235,118
| +65% | +$15.2M |
|
21
Align Technology
ALGN
$12.7B
| $29.1M | 1.33% |
512,393
+38,871
| +8% | +$2.32M |
|
22
DexCom
DXCM
$29.6B
| $27.8M | 1.27% |
1,292,932
-299,700
| -19% | -$6.69M |
|
|
SHPG
23
DELISTED
Shire pic
SHPG
| $25.1M | 1.15% |
122,056
+8,244
| +7% | +$1.96M |
|
|
ALDR
24
DELISTED
Alder Biopharmaceuticals
ALDR
| $25M | 1.14% |
762,682
+79,946
| +12% | +$3.4M |
|
25
United Therapeutics
UTHR
$22.7B
| $23.1M | 1.06% |
175,780
| – | – |
|
Similar funds
RIP
CCM
LFWA
FWA
CF
WIM
MW
AFC
Sectoral Asset Management's Q3 2015 Portfolio in Review
As of Q3 2015, Sectoral Asset Management held 100 positions worth $2.18B, down 9% from $2.4B the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Sectoral Asset Management deployed $233M of net new capital in Q3 2015, opening 9 new positions and adding to 46 existing holdings. Its largest new stake was Sierra Oncology, Inc. Common Stock: 21,569 shares worth $17.3M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 91% a quarter earlier.
On the sell side, the largest reduction was ZS PHARMA INC COMS TK (DE), an estimated $25.4M trimmed.
- Sectoral Asset Management's largest Q3 2015 buy was Sierra Oncology, Inc. Common Stock: 21,569 shares worth $17.3M.
- Sectoral Asset Management added most to Gilead Sciences in Q3 2015, an estimated $61.3M increase.
- Sectoral Asset Management's biggest Q3 2015 reduction was ZS PHARMA INC COMS TK (DE), cutting an estimated $25.4M.
- Sectoral Asset Management fully exited Abbott in Q3 2015, selling an estimated $26.6M.
- Sectoral Asset Management's ten largest holdings make up 53% of its $2.18B portfolio in Q3 2015.
- Sectoral Asset Management opened 9 new positions and closed 23 in Q3 2015.
- Sectoral Asset Management's portfolio value fell 9% quarter-over-quarter to $2.18B.
Based on Sectoral Asset Management's 13F filing for Q3 2015, filed 13 Nov 2015.